PBYI
Puma Biotechnology Inc

6,885
Mkt Cap
$288.74M
Volume
355,316.00
52W High
$6.12
52W Low
$2.58
PE Ratio
7.91
PBYI Fundamentals
Price
$5.86
Prev Close
$5.73
Open
$5.72
50D MA
$5.18
Beta
0.85
Avg. Volume
681,976.32
EPS (Annual)
$0.6166
P/B
2.56
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Acorn Capital Advisors LLC Has $14.17 Million Stake in Puma Biotechnology, Inc. $PBYI
Acorn Capital Advisors LLC grew its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 4.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
American Century Companies Inc. Grows Stake in Puma Biotechnology, Inc. $PBYI
American Century Companies Inc. grew its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 16.8% in the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·5d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Time to Sell...
MarketBeat·11d ago
News Placeholder
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Zacks·16d ago
News Placeholder
LSV Asset Management Purchases 482,340 Shares of Puma Biotechnology, Inc. $PBYI
LSV Asset Management increased its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 903.3% in the second quarter, according to the company in its most recent filing with...
MarketBeat·21d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Buys 68,567 Shares of Puma Biotechnology, Inc. $PBYI
Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 8.2% during the 2nd quarter, according to the company in its...
MarketBeat·27d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Director Sells $97,200.00 in Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 20,000 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an...
MarketBeat·28d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Director Michael Patrick Miller Sells 20,000 Shares
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 20,000 shares of Puma Biotechnology stock in a transaction dated Tuesday, November 11th. The stock was...
MarketBeat·29d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts' consensus...
MarketBeat·1mo ago
News Placeholder
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
Zacks·1mo ago

Latest PBYI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.